Educational use only. Check doses against the product monograph and local protocols.

phosphate binders

in review 3 min read Updated 2026-10-27
phosphate binders

Bind dietary phosphate in the gut; taken with meals. KDIGO 2017: start only for persistent or progressive hyperphosphataemia, lower phosphate towards normal, restrict calcium-based binders (2B), never long-term aluminium (1C). Diet (additives) and, on dialysis, more dialytic removal come first or alongside.

mechanism

Non-absorbed cation (Ca²⁺, La³⁺, Fe³⁺) or resin (sevelamer) complexes dietary phosphate in the gut lumen.


agents

agentclasskey points
calcium carbonate / acetatecalcium-basedcheap. Positive calcium balance and more coronary calcification (calcium acetate arm, Block et al.) → restrict dose in everyone (2017 dropped the hypercalcaemia qualifier); especially undesirable with hypercalcaemia, calcification or low PTH
sevelamer (carbonate)calcium-free resinno calcium load. Survival benefit vs calcium binders in 2 RCTs (moderate risk of bias). GI upset, high pill burden; lowers LDL; binds some drugs
lanthanum carbonatecalcium-free metalchewable, fewer tablets. GI effects
iron-based (sucroferric oxyhydroxide, ferric citrate)calcium-freeferric citrate also delivers iron. Dark stools
aluminium hydroxide—avoid long term (neuro- and bone toxicity)
agentstarting dose (dialysis)titration
sevelamer carbonate or HCl 800 mgPO₄ 1.8–2.4 → 1 tab TID with meals; ≥2.4 → 2 tabs TID±1 tab per meal every 1–3 weeks; average maintenance ~3 tabs per meal
lanthanum carbonate (chewable)750–1500 mg/day, divided with mealsevery 2–3 weeks
sucroferric oxyhydroxide 500 mg iron1 tab TID with meals±1 tab/day every 2–4 weeks; usual 3–4/day, max 6
  • Dose to meal phosphate content, split across meals (bigger meal → more tablets). Adjust by trend over weeks

key points

  • Normal phosphate isn’t an indication: binders in normophosphataemic G3b–G4 lowered urinary phosphate but didn’t change FGF23, and the calcium arm progressed calcification
  • Even calcium-free binders have harms (GI, binding nutrients) → don’t start them preventively
  • Targets, dialysate Ca, PTH ranges and calcitriol/calcimimetic choice → ckd complications. On dialysis, longer or more frequent sessions also clear phosphate
  • Cinacalcet lowers Ca → watch for hypocalcaemia (EVOLVE (2012): primary endpoint not significant, HR 0.93)
  • Drug binding (Health Canada monographs): ciprofloxacin (sevelamer halves bioavailability), levothyroxine (↑TSH; check TSH), and with sevelamer, ciclosporin/tacrolimus/mycophenolate (lower levels post-transplant) → give the other drug ≥1 h before or 3 h after sevelamer; ≥1 h before sucroferric (doxycycline: or 2 h after); lanthanum: not simultaneously with quinolones or thyroxine, and 2 h apart from tetracyclines/doxycycline
calcium load

Calcium-based binders + calcitriol + high-calcium dialysate → hypercalcaemia, adynamic bone, vascular calcification. KDIGO removed the old “only if hypercalcaemic” qualifiers: limit calcium exposure in everyone.


adverse effects

  • Calcium salts: hypercalcaemia, constipation, calcification
  • Sevelamer: bloating, constipation; dysphagia, bowel obstruction and perforation (boxed warning; contraindicated in bowel obstruction); metabolic acidosis with the hydrochloride form
  • Lanthanum: nausea; tablets must be chewed fully (unchewed → serious GI complications); contraindicated in bowel obstruction, ileus, faecal impaction
  • Iron-based: diarrhoea, black stools (can mask GI bleeding)
  • Aluminium: encephalopathy, osteomalacia, microcytic anaemia

Prepared 2026-10-27. Not yet verified — check every number against the sources.

Key references

+5 more sources

Suggest a correction phosphate binders